A review of the treatment of male pattern hair loss

References

• Hamilton JB. Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci. 1951;53:708–728.
   PubMed Web of Science ®Google Scholar
• Rhodes T, Girman CJ, Savin RC, et al. Prevalence of male pattern hair loss in 18–49 year old men. Dermatol Surg. 1998;24:1330–1332.
   PubMed Web of Science ®Google Scholar
• Severi G, Sinclair R, Hopper J, et al. Androgenetic alopecia in men aged 40–69 years: prevalence and risk factors. Br J Dermatol. 2003;149:1207–1213.
   PubMed Web of Science ®Google Scholar
• Paik JH, Yoon JB, Sim WY, et al. The prevalence and types of androgenetic alopecia in Korean men and women. Br J Dermatol. 2001;145:95–99.
   PubMed Web of Science ®Google Scholar
• Lee W-S, Lee H-J. Characteristics of androgenetic alopecia in asian. Ann Dermatol. 2012;24:243–252.
   PubMed Web of Science ®Google Scholar
• Cash TF. The psychological effects of androgenetic alopecia in men. J Am Acad Dermatol. 1992;26:926–931.
   PubMed Web of Science ®Google Scholar
• Girman C, Rhodes T, Lilly F, et al. Effects of self-perceived hair loss in a community sample of men. Dermatology. 1998;197:223–229.
   PubMed Web of Science ®Google Scholar
• Marcińska M, Pośpiech E, Abidi S, et al. Evaluation of DNA variants associated with androgenetic alopecia and their potential to predict male pattern baldness. PloS One. 2015;10:e0127852.
   PubMed Web of Science ®Google Scholar
• Price VH. Treatment of hair loss. N Engl J Med. 1999;341:964–973.
   PubMed Web of Science ®Google Scholar
• Rossi A, Cantisani C, Scarnò M, et al. Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10‐year follow‐up. Dermatol Ther. 2011;24:455–461.
   PubMed Web of Science ®Google Scholar
• Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39:578–589.
   PubMed Web of Science ®Google Scholar
• Mella JM, Perret MC, Manzotti M, et al. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol. 2010;146:1141–1150.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Charrette A. The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit–risk assessment of finasteride and dutasteride. J Dermatological Treat. 2014;25:156–161.
   PubMed Web of Science ®Google Scholar
• Leyden J, Dunlap F, Miller B, et al. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol. 1999;40:930–937.
   PubMed Web of Science ®Google Scholar
• Blumeyer A, Tosti A, Messenger A, et al. Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges. 2011;9:S1–S57.
   PubMed Web of Science ®Google Scholar
• Rahimi-Ardabili B, Pourandarjani R, Habibollahi P, et al. Finasteride induced depression: a prospective study. BMC Clin Pharmacol. 2006;6:7.
   PubMedGoogle Scholar
• Rossi A, Mari E, Scarno M, et al. Comparitive effectiveness and finasteride vs serenoa repens in male androgenetic alopecia: a two-year study. Int J Immunopathol Pharmacol. 2012;25:1167–1173.
   PubMed Web of Science ®Google Scholar
• Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med. 2011;8:1747–1753.
   PubMed Web of Science ®Google Scholar
• Irwig MS. Persistent sexual side effects of finasteride: could they be permanent? J Sex Med. 2012;9:2927–2932.
   PubMed Web of Science ®Google Scholar
• Irwig MS. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. J Clin Psychiatry. 2012;73:1220–1223.
   PubMed Web of Science ®Google Scholar
• Group FMPHLS. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol. 2002;12:38–49.
   PubMed Web of Science ®Google Scholar
• Thompson IM Jr, Goodman PJ, Tangen CM, et al. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med. 2013;369:603–610.
   PubMed Web of Science ®Google Scholar
• Cohen YC, Liu KS, Heyden NL, et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the prostate cancer prevention trial. J Natl Cancer Inst. 2007;99:1366–1374.
   PubMed Web of Science ®Google Scholar
• D’Amico AV, Roehrborn CG. Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol. 2007;8:21–25.
   PubMed Web of Science ®Google Scholar
• Shanshanwal SJ, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Indian J Dermatol Venereol Leprol. 2017;83:47.
   PubMed Web of Science ®Google Scholar
• Tsunemi Y, Irisawa R, Yoshiie H, et al. Long‐term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia. J Dermatol. 2016;43:1051–1058.
   PubMed Web of Science ®Google Scholar
• Harcha WG, Martínez JB, Tsai T-F, et al. A randomized, active-and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(489–498):e483.
   Google Scholar
• Jung JY, Yeon JH, Choi JW, et al. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. Int J Dermatol. 2014;53:1351–1357.
   PubMed Web of Science ®Google Scholar
• Lee SW, Juhasz M, Mobasher P, et al. A systematic review of topical finasteride in the treatment of androgenetic alopecia in men and women. J Drugs Dermatol. 2018;17:457.
   PubMed Web of Science ®Google Scholar
• Suchonwanit P, Srisuwanwattana P, Chalermroj N, et al. A randomized, double‐blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. J Eur Acad Dermatol Venereol. 2018;32:2257–2263.
   PubMed Web of Science ®Google Scholar
• Roberts J, Desai N, McCoy J, et al. Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil in the treatment of female androgenetic alopecia. Dermatol Ther. 2014;27:252–254.
   PubMed Web of Science ®Google Scholar
• Jahangir A, Terzic A. KATP channel therapeutics at the bedside. J Mol Cell Cardiol. 2005;39:99–112.
   PubMed Web of Science ®Google Scholar
• Marubayashi A, Nakaya Y, Fukui K, et al. Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. J Invest Dermatol. 2001;117:1594–1600.
   PubMed Web of Science ®Google Scholar
• Messenger A, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150:186–194.
   PubMed Web of Science ®Google Scholar
• Sharma A, Goren A, Dhurat R, et al. Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. Dermatol Ther. 2019 May;32(3):e12915.
   PubMed Web of Science ®Google Scholar
• Goren A, Sharma A, Dhurat R, et al. Low‐dose daily aspirin reduces topical minoxidil efficacy in androgenetic alopecia patients. Dermatol Ther. 2018;31:e12741.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47:377–385.
   PubMed Web of Science ®Google Scholar
• Goren A, Shapiro J, Roberts J, et al. Clinical utility and validity of minoxidil response testing in androgenetic alopecia. Dermatol Ther. 2015;28:13–16.
   PubMed Web of Science ®Google Scholar
• De Villez RL. Topical minoxidil therapy in hereditary androgenetic alopecia. Arch Dermatol. 1985;121:197–202.
   PubMedGoogle Scholar
• Olsen EA, Weiner MS. Topical minoxidil in male pattern baldness: effects of discontinuation of treatment. J Am Acad Dermatol. 1987;17:97–101.
   PubMed Web of Science ®Google Scholar
• Ebner H, Müller E. Allergic contact dermatitis from minoxidil. Contact Dermatitis. 1995;32:316–317.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Whiting D, Bergfeld W, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007;57:767–774.
   PubMed Web of Science ®Google Scholar
• Saraswat A, Kumar B. Minoxidil vs finasteride in the treatment of men with androgenetic alopecia. Arch Dermatol. 2003;139:1219–1221.
   PubMedGoogle Scholar
• Khandpur S, Suman M and Reddy BS. Comparative efficacy of various treatment regimens for androgenetic alopecia in men. J Dermatol. 2002;29:489–498.
   PubMed Web of Science ®Google Scholar
• Hu R, Xu F, Sheng Y, et al. Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized and comparative study in Chinese patients. Dermatol Ther. 2015;28:303–308.
   PubMed Web of Science ®Google Scholar
• Arca E, Açıkgöz G, Taştan HB, et al. An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia. Dermatology. 2004;209:117–125.
   PubMed Web of Science ®Google Scholar
• Zappacosta AR. Reversal of baldness in patients receiving minoxidil for hypertension. New Engl J Med. 1980;303:1480–1481.
   PubMed Web of Science ®Google Scholar
• Jimenez-Cauhe J, Saceda-Corralo D, Rodrigues-Barata A, et al. Effectiveness and safety of low-dose oral minoxidil for male androgenetic alopecia. J Am Acad Dermatol. 2019 Aug;81(2):648–649.
   Google Scholar
• Lueangarun S, Panchaprateep R, Tempark T, et al. Efficacy and safety of oral minoxidil 5 mg daily during 24-week treatment in male androgenetic alopecia. J Am Acad Dermatol. 2015.
   Google Scholar
• Khidhir KG, Woodward DF, Farjo NP, et al. The prostamide-related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias. Faseb J. 2013;27:557–567.
   PubMed Web of Science ®Google Scholar
• Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol. 2002;47:S185–S202.
   PubMed Web of Science ®Google Scholar
• Garza LA, Liu Y, Yang Z, et al. Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med. 2012;4:126ra134–126ra134.
   Web of Science ®Google Scholar
• Cohen JL. Enhancing the growth of natural eyelashes: the mechanism of bimatoprost‐induced eyelash growth. Dermatol Surg. 2010;36:1361–1371.
   PubMed Web of Science ®Google Scholar
• Barrón-Hernández YL, Tosti A. Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia. Expert Opin Investig Drugs. 2017;26:515–522.
   PubMed Web of Science ®Google Scholar
• Duke University. Topical bimatoprost effect on androgen dependent hair follicles. [cited 2019 Aug 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT02170662
   Google Scholar
• Blume-Peytavi U, Lönnfors S, Hillmann K, et al. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol. 2012;66:794–800.
   PubMed Web of Science ®Google Scholar
• Charlesworth E, Kagey-Sobotka A, Norman PS, et al. Effect of cetirizine on mast cell-mediator release and cellular traffic during the cutaneous late-phase reaction. J Allergy Clin Immunol. 1989;83:905–912.
   PubMed Web of Science ®Google Scholar
• Rossi A, Campo D, Fortuna M, et al. A preliminary study on topical cetirizine in the therapeutic management of androgenetic alopecia. J Dermatological Treat. 2018;29:149–151.
   PubMed Web of Science ®Google Scholar
• Allergan. A safety and efficacy study of setipiprant tablets in androgenetic alopecia in males. [cited 2019 Aug 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT02781311
   Google Scholar
• Lee S-H, Yoon J, Shin SH, et al. Valproic acid induces hair regeneration in murine model and activates alkaline phosphatase activity in human dermal papilla cells. PLoS One. 2012;7:e34152.
   PubMed Web of Science ®Google Scholar
• Jo SJ, Shin H, Park YW, et al. Topical valproic acid increases the hair count in male patients with androgenetic alopecia: a randomized, comparative, clinical feasibility study using phototrichogram analysis. J Dermatol. 2014;41:285–291.
   PubMed Web of Science ®Google Scholar
• Prager N, Bickett K, French N, et al. A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-α-reductase in the treatment of androgenetic alopecia. J Altern Complementary Med. 2002;8:143–152.
   PubMed Web of Science ®Google Scholar
• Wilt T, Ishani A, Stark G, et al. Serenoa repens for benign prostatic hyperplasia (Cochrane Review). Cochrane Lib. 2002;2:3.
   Google Scholar
• Fasulo C, Linguiti A, Bosco L, et al. Effectiveness of serenoa repens on androgenetic alopecia: P10. 141. J Dtsch Dermatol Ges. 2004;2:10.
   Google Scholar
• Won CH, Park G-H, Wu X, et al. The basic mechanism of hair growth stimulation by adipose-derived stem cells and their secretory factors. Curr Stem Cell Res Ther. 2017;12:535–543.
   PubMed Web of Science ®Google Scholar
• Marx RE. Platelet-rich plasma: evidence to support its use. J Oral Maxillofacial Surg. 2004;62:489–496.
   PubMed Web of Science ®Google Scholar
• Giordano S. Romeo M and Lankinen P. Platelet‐rich plasma for androgenetic alopecia: does it work? Evidence from meta analysis. J Cosmet Dermatol. 2017;16:374–381.
   PubMed Web of Science ®Google Scholar
• Eppley BL. Woodell JE and Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg. 2004;114:1502–1508.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Carviel J. A mechanistic model of platelet-rich plasma treatment for androgenetic alopecia. Dermatol Surg. 2016;42:1335–1339.
   PubMed Web of Science ®Google Scholar
• Rodrigues BL, Montalvão SA, Cancela RB, et al. Treatment of male pattern alopecia with platelet-rich plasma: A double-blind controlled study with analysis of platelet number and growth factor levels. J Am Acad Dermatol. 2019;80:694–700.
   PubMed Web of Science ®Google Scholar
• Gentile P, Garcovich S, Bielli A, et al. The effect of platelet‐rich plasma in hair regrowth: a randomized placebo‐controlled trial. Stem Cells Transl Med. 2015;4:1317–1323.
   PubMed Web of Science ®Google Scholar
• Fertig R, Gamret A, Cervantes J, et al. Microneedling for the treatment of hair loss? J Eur Acad Dermatol Venereol. 2018;32:564–569.
   PubMed Web of Science ®Google Scholar
• Dhurat R, Sukesh M, Avhad G, et al. A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study. Int J Trichology. 2013;5:6.
   PubMedGoogle Scholar
• Zarei M, Wikramanayake TC, Falto-Aizpurua L, et al. Low level laser therapy and hair regrowth: an evidence-based review. Lasers Med Sci. 2016;31:363–371.
   PubMed Web of Science ®Google Scholar
• Avci P, Gupta GK, Clark J, et al. Low‐level laser (light) therapy (LLLT) for treatment of hair loss. Lasers Surg Med. 2014;46:144–151.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Foley KA. A critical assessment of the evidence for low-level laser therapy in the treatment of hair loss. Dermatol Surg. 2017;43:188–197.
   PubMed Web of Science ®Google Scholar
• Chung H, Dai T, Sharma SK, et al. The nuts and bolts of low-level laser (light) therapy. Ann Biomed Eng. 2012;40:516–533.
   PubMed Web of Science ®Google Scholar
• Karu T. Primary and secondary mechanisms of action of visible to near-IR radiation on cells. J Photochem Photobiol B Biol. 1999;49:1–17.
   PubMed Web of Science ®Google Scholar
• Heiskanen V, Hamblin MR. Photobiomodulation: lasers vs. light emitting diodes?. Photochem Photobiol Sci. 2018;17:1003–1017.
   PubMed Web of Science ®Google Scholar
• Gupta A, Carviel J. Meta-analysis of photobiomodulation for the treatment of androgenetic alopecia. J Dermatological Treat. 2019;19:1–5.
   Web of Science ®Google Scholar
• Perper M, Aldahan AS, Fayne RA, et al. Efficacy of fractional lasers in treating alopecia: a literature review. Lasers Med Sci. 2017;32:1919–1925.
   PubMed Web of Science ®Google Scholar
• Meephansan J, Ungpraphakorn N, Ponnikorn S, et al. Efficacy of 1,550-nm erbium-glass fractional laser treatment and its effect on the expression of insulin-like growth factor 1 and Wnt/β-catenin in androgenetic alopecia. Dermatol Surg. 2018;44:1295–1303.
   PubMed Web of Science ®Google Scholar
• KIM WS, Lee HI, Lee JW, et al. Fractional photothermolysis laser treatment of male pattern hair loss. Dermatol Surg. 2011;37:41–51.
   PubMed Web of Science ®Google Scholar
• Suchonwanit P. Rojhirunsakool S and Khunkhet S. A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia. Lasers Med Sci. 2019;34:1856–1864.
   Web of Science ®Google Scholar
• Hawkshaw NJ, Hardman JA, Haslam IS, et al. Identifying novel strategies for treating human hair loss disorders: cyclosporine A suppresses the Wnt inhibitor, SFRP1, in the dermal papilla of human scalp hair follicles. PLoS Biol. 2018;16:e2003705.
   PubMed Web of Science ®Google Scholar
• Choi H-I, Kang B-M, Jang J, et al. Novel effect of sildenafil on hair growth. Biochem Biophys Res Commun. 2018;50:685691.
   Google Scholar
• Nyholt DR, Gillespie NA, Heath AC, et al. Genetic basis of male pattern baldness. J Invest Dermatol. 2003;121:1561–1564.
   PubMed Web of Science ®Google Scholar
• Hagenaars SP, Hill WD, Harris SE, et al. Genetic prediction of male pattern baldness. PLoS Genet. 2017;13:e1006594.
   PubMed Web of Science ®Google Scholar
• Ellis JA. Stebbing M and Harrap SB. Polymorphism of the androgen receptor gene is associated with male pattern baldness. J Invest Dermatol. 2001;116:452–455.
   PubMed Web of Science ®Google Scholar
• Cobb J, Wong N, Yip L, et al. Evidence of increased DNA methylation of the androgen receptor gene in occipital hair follicles from men with androgenetic alopecia. Br J Dermatol. 2011;165:210–213.
   PubMed Web of Science ®Google Scholar
• Orentreich N. Autografts in alopecias and other selected dermatological conditions. Ann N Y Acad Sci. 1959;83:463–479.
   PubMed Web of Science ®Google Scholar
• Messenger A, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150:186–194.
   PubMed Web of Science ®Google Scholar
• Buhl AE, Waldon DJ, Kawabe TT, et al. Minoxidil stimulates mouse vibrissae follicles in organ culture. J Invest Dermatol. 1989;92:315–320.
   PubMed Web of Science ®Google Scholar
• George M Efficacy study of a cosmetic lotion in the treatment of androgenetic alopecia in males and females (MEXISPATENT). [cited 2019 Aug 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT01701271
   Google Scholar
• LLC S A study of SM04554 applied topically to the scalp of male subjects with androgenetic alopecia analyzed by biopsy of the scalp prior to and post dosing. [cited 2019 Aug 24]. Available from: https://clinicaltrials.gov/ct2/show/NCT02503137
   Google Scholar
• Applied Biology I. Minoxidil response testing in males with androgenetic alopecia. [cited 2019 Aug 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT02198261
   Google Scholar
• RepliCel Life Sciences ITI, Inc. Safety and efficacy study of human autologous hair follicle cells to treat androgenetic alopecia. [cited 2019 Aug 24]. Available from: https://clinicaltrials.gov/ct2/show/NCT01286649
   Google Scholar
• Aclaris Therapeutics I. A study in male and female subjects with androgenetic alopecia treated with ATI-50002 topical solution. [cited 2019 Aug 24]. Available from: https://clinicaltrials.gov/ct2/show/NCT03495817
   Google Scholar
• Masoud F Efficacy and safety study to compare topical herbal solution and minoxidil 5% in male pattern hair loss. [cited 2019 Aug 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT03753113
   Google Scholar
• AB F To investigate efficacy of FOL-005 on hair growth on scalp skin. [cited 2019 Aug 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT03467412
   Google Scholar
• LLC S A study evaluating the efficacy and safety of SM04554 topical solution in male subjects with androgenetic alopecia. [cited 2019 Aug 24]. Available from: https://clinicaltrials.gov/ct2/show/NCT03742518
   Google Scholar
• RL SA. Evaluate the clinical effectiveness of regenkit platelet-rich plasma (PRP) in androgenetic alopecia treatment. [cited 2019 Aug 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT02591355
   Google Scholar
• University A Adipose derived stem cells versus platelet rich plasma on follicular unit extraction. [cited 2019 Aug 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT03388840
   Google Scholar
• Institute UoM-CaTS. Laser assisted delivery of minoxidil in androgenetic alopecia. [cited 2019 Aug 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT03852992
   Google Scholar
• Inc AT. Low level light therapy (LLLT) for hair growth. [cited 2019 Aug 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT03938948
   Google Scholar
• Hospital SKWH-SM. The effect of microneedling with low energy laser in androgenic alopecia patients. [cited 2019 Aug 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT03723369
   Google Scholar